Last reviewed · How we verify
Zaditor (KETOTIFEN)
At a glance
| Generic name | KETOTIFEN |
|---|---|
| Sponsor | Bausch And Lomb |
| Drug class | Histamine-1 Receptor Inhibitor |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
| First approval | 1999 |
Approved indications
- Allergic conjunctivitis
Common side effects
Key clinical trials
- Topical Ketotifen 0.25% for Secondary Vestibulodynia (PHASE2)
- Ketotifen in Non-Alcoholic Fatty Liver Disease Patients (PHASE4)
- Ketotifen for Children With Functional Dyspepsia in Association With Duodenal Eosinophilia (PHASE3)
- A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis (PHASE3)
- PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2 (PHASE3)
- A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
- Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution (PHASE3)
- Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zaditor CI brief — competitive landscape report
- Zaditor updates RSS · CI watch RSS